Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101
- 30 January 2008
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 158 (3), 578-586
- https://doi.org/10.1111/j.1365-2133.2007.08414.x
Abstract
Background The immunomodulator AS101 [ammonium trichloro (dioxoethylene-O,O’) tellurate], a nontoxic tellurium (IV) compound, has antitumoral effects which were demonstrated in several preclinical and clinical studies. Objectives To investigate the antitumour activity of AS101 on cutaneous T-cell lymphoma (CTCL), of which mycosis fungoides (MF) is the most frequent disease variant. Methods We used a newly established mouse xenograft model for MF to test the effect of AS101 in vivo and analysed apoptosis induction in vitro. Results When injected intratumorally, AS101 delayed tumour growth in a dose-dependent manner. In vitro, AS101 induced a dose-dependent G2/M arrest in the CTCL cell lines Hut78 and MyLa. Moreover, higher concentrations of AS101 induced apoptosis in MyLa cells. Programmed cell death was associated with the loss of mitochondrial transmembrane potential and activation of caspase 9 and caspase 3. AS101 also elevated intracellular reactive oxygen species (ROS) production; the antioxidant, Mn superoxide dismutase, significantly reduced the degree of apoptosis, suggesting that ROS play a key role in apoptosis induction. Conclusions These findings indicate that AS101 may be a promising antitumour drug for CTCL.Keywords
This publication has 39 references indexed in Scilit:
- Green Tea Component, Catechin, Induces Apoptosis of Human Malignant B Cells via Production of Reactive Oxygen SpeciesClinical Cancer Research, 2005
- Establishment of a mouse xenograft model for mycosis fungoidesExperimental Dermatology, 2004
- Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras‐dependent up‐regulation of KGF expressionThe FASEB Journal, 2003
- Phase II trial of interferon‐α‐2a plus psolaren with ultraviolet light A in patients with cutaneous T‐cell lymphomaCancer, 2002
- Proteases to die forGenes & Development, 1998
- The Immunomodulator AS-101 Inhibits IL-10 Release and Augments TNFα and IL-1α Release by Mouse and Human Mononuclear PhagocytesCellular Immunology, 1997
- Progression of Mycosis Fungoides Is Associated with Increasing Cutaneous Expression of Interleukin-10 mRNAJournal of Investigative Dermatology, 1996
- Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS 101JNCI Journal of the National Cancer Institute, 1996
- Low-Level Oxidative Stress Causes Cell Cycle-Specific Arrest in Cultured CellsBiochemical and Biophysical Research Communications, 1995
- A new immunomodulating compound (AS-101) with potential therapeutic applicationNature, 1987